专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010011926A3 A NOVEL BETAINE COCRYSTAL OF EPALRESTAT 审中-公开
标题翻译： EPALRESTAT的新型BETAINE COCRYSTAL
公开(公告)号：WO2010011926A3
公开(公告)日：2010-05-27
申请号：PCT/US2009051693
申请日：2009-07-24
申请人： BIONEVIA PHARMACEUTICALS INC , KALOFONOS ISABEL , STAHLY PATRICK G , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HOUSTON TRAVIS L
发明人： KALOFONOS ISABEL , STAHLY PATRICK G , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HOUSTON TRAVIS L
IPC分类号： C07D277/36 , A61K31/20 , A61K31/25 , A61P3/10
CPC分类号： A61K31/20 , A61K31/25 , C07D277/36
摘要： The invention relates to a novel betaine cocrystal of 5-[(lZ,2E)-2-methyl-3- phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel betaine cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel betaine cocrystal and the therapeutic use of the novel betaine cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria, reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.
摘要翻译：本发明涉及5 - [（1Z，2E）-2-甲基-3-苯基亚丙烯基] -4-氧代-2-硫代-3-噻唑烷乙酸的新型甜菜碱共结晶。描述了根据本发明的各种实施方式的新型甜菜碱共晶的制备和表征。本发明还涉及含有新型甜菜碱共晶体的药物组合物和新型甜菜碱共晶体的治疗用途，以治疗和/或预防各种病症，包括治疗和/或预防糖尿病并发症，治疗和/或预防高胱氨酸尿症，降低高半胱氨酸水平在血清中，抑制醛糖还原酶，并在非糖尿病患者中提供心脏保护。

2. 发明申请

WO2010011922A3 NOVEL CRYSTALLINE SALTS OF EPALRESTAT 审中-公开
标题翻译： EPALRESTAT的新型结晶盐
公开(公告)号：WO2010011922A3
公开(公告)日：2010-04-22
申请号：PCT/US2009051687
申请日：2009-07-24
申请人： BIONEVIA PHARMACEUTICALS INC , KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HOUSTON TRAVIS L
发明人： KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HOUSTON TRAVIS L
IPC分类号： C07D277/36 , A61K31/41 , A61K31/42 , A61P3/10 , C07D277/593 , C07F1/06
CPC分类号： C07D277/36 , A61K31/41 , A61K31/42
摘要： The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3- phenyIpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the crystalline salts according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and the therapeutic use of the novel crystalline salts to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.
摘要翻译：本发明涉及5 - [（1Z，2E）-2-甲基-3-苯基亚丙叉基] -4-氧代-2-硫代-3-噻唑烷乙酸的新结晶盐。描述根据本发明的各种实施方案的结晶盐的制备和表征。本发明还涉及含有新型结晶盐的新型结晶盐和治疗和/或预防各种病症的治疗用途的药物组合物，包括治疗和/或预防糖尿病并发症，抑制醛糖还原酶，以及在患者中提供心脏保护非糖尿病

3. 发明申请

WO2010028132A2 NOVEL CHOLINE COCRYSTAL OF EPALRESTAT 审中-公开
标题翻译： EPALRESTAT的新型胆碱共晶体
公开(公告)号：WO2010028132A2
公开(公告)日：2010-03-11
申请号：PCT/US2009055868
申请日：2009-09-03
申请人： BIONEVIA PHARMACEUTICALS INC , KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HOUSTON TRAVIS L
发明人： KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HOUSTON TRAVIS L
IPC分类号： C07D277/36 , A61K31/19 , A61P3/10 , C07D277/32
CPC分类号： C07D277/36 , A61K31/14 , A61K31/426 , A61K31/427 , C07B2200/13 , C07C215/40
摘要： The invention relates to a novel choline cocrystal of 5-[(lZ.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.
摘要翻译：本发明涉及5 - [（1Z，2E）-2-甲基-3-苯基亚丙烯基] -4-氧代-2-硫代-3-噻唑烷乙酸的新型胆碱共结晶。描述了根据本发明的各种实施方式的新型胆碱共晶的制备和表征。本发明还涉及含有该新型胆碱共结晶的药物组合物以及该新型胆碱共结晶的治疗用途，用于治疗和/或预防包括治疗和/或预防糖尿病并发症，治疗和/或预防高胱氨酸尿症血清，抑制醛糖还原酶，并在非糖尿病患者中提供心脏保护。

4. 发明申请

WO2010017135A3 NOVEL FORMS OF EPERISONE 审中-公开
标题翻译： EPERISONE的新形式
公开(公告)号：WO2010017135A3
公开(公告)日：2010-05-14
申请号：PCT/US2009052575
申请日：2009-08-03
申请人： BIONEVIA PHARMACEUTICALS INC , KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , HANKO JASON A , STULTS JEFFREY S , KIPLINGER JEFFREY P
发明人： KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , HANKO JASON A , STULTS JEFFREY S , KIPLINGER JEFFREY P
IPC分类号： C07D211/34 , A61K31/445 , A61P21/02
CPC分类号： C07D295/108
摘要： The invention relates to substantially enantiopure crystalline salt forms of (2RS)-I -(4- Ethylphenyl)-2-methyl-3-piperidin-l-ylpropan-l-one. The preparation and characterization of the substantially enantiopure crystalline salt forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the substantially enantiopure crystalline salt forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotome conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.
摘要翻译：本发明涉及（2RS）-1-（4-乙基苯基）-2-甲基-3-哌啶-1-基丙-1-酮的基本对映体纯的结晶盐形式。描述根据本发明的各种实施方案的基本对映体纯的结晶盐形式的制备和表征。本发明还涉及含有基本上对映体纯的结晶盐形式的药物组合物，其可用于治疗和/或预防各种病症如病理性肌肉挛缩，肌肉破裂症状，以及由各种神经病症引起的痉挛性麻痹或痉挛状态，并且也是有用的用于治疗和/或预防各种类型的疼痛和病理性肌肉紧张。

5. 发明申请

WO2010017343A3 FLUPIRTINE HYDROCHLORIDE MALEIC ACID COCRYSTAL 审中-公开
标题翻译： FLUPIRTINE HYDROCHLORIDE马来酸共晶体
公开(公告)号：WO2010017343A3
公开(公告)日：2010-05-14
申请号：PCT/US2009052925
申请日：2009-08-06
申请人： BIONEVIA PHARMACEUTICALS INC , KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HANKO JASON A , SHIPPLETT REX A
发明人： KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HANKO JASON A , SHIPPLETT REX A
IPC分类号： C07D213/75 , A61K31/44 , A61P25/00 , A61P25/04 , C07D211/36
CPC分类号： C07D213/75
摘要： The invention relates to crystalline forms of flupirtine, particularly to 1:1 flupirtine hydrochloride maleic acid cocrystal. The preparation and characterization of 1:1 flupirtine hydrochloride maleic acid cocrystal is described. The invention also relates to the therapeutic use of the flupirtine hydrochloride maleic acid cocrystal to treat nervous system disorders, pain disorders, and musculoskeletal disorders and to pharmaceutical compositions containing the cocrystal.
摘要翻译：本发明涉及氟吡汀的结晶形式，特别涉及1:1氟吡汀盐酸盐马来酸共结晶。描述了1:1氟吡汀盐酸盐马来酸共晶体的制备和表征。本发明还涉及氟吡汀盐酸盐马来酸共晶体治疗神经系统疾病，疼痛疾病和肌肉骨骼疾病的治疗用途以及含有该共晶体的药物组合物。

6. 发明申请

WO2010081070A3 NOVEL FORMS OF EPERISONE 审中-公开
标题翻译：新型EPERISONE
公开(公告)号：WO2010081070A3
公开(公告)日：2010-10-28
申请号：PCT/US2010020614
申请日：2010-01-11
申请人： BIONEVIA PHARMACEUTICALS INC , KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HANKO JASON A
发明人： KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HANKO JASON A
IPC分类号： C07D211/34 , A61K31/445 , A61P21/02
CPC分类号： C07D295/108 , A61K31/445
摘要： The invention relates to novel crystalline forms of (2RS)-1 -(4-ethylphenyl)-2-methyl-3- piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotonic conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.
摘要翻译：（2RS）-1-（4-乙基苯基）-2-甲基-3-哌啶-1-基 - 丙-1-酮的新结晶形式本发明涉及（2RS）-1-（4-乙基苯基）-2-甲基-3-哌啶-1-基 - 丙-1-酮的新结晶形式。描述了根据本发明的各种实施方式的新颖结晶形式的制备和表征。本发明还涉及含有新型晶型的药物组合物，其可用于治疗和/或预防各种病症如病理性肌肉挛缩，肌强直症状和由各种神经病症引起的痉挛性瘫痪或痉挛状态，并且也可用于治疗和/或预防各种类型的疼痛和病理性肌肉紧张。

7. 发明申请

WO2009027909A3 APPARATUS AND METHOD FOR MANAGING ACCESS TO ONE OR MORE NETWORK RESOURCES 审中-公开
标题翻译：用于管理访问一个或多个网络资源的装置和方法
公开(公告)号：WO2009027909A3
公开(公告)日：2009-04-30
申请号：PCT/IB2008053360
申请日：2008-08-21
申请人： NOKIA CORP , KALOFONOS DIMITRIS , REYNOLDS FRANKLIN
发明人： KALOFONOS DIMITRIS , REYNOLDS FRANKLIN
IPC分类号： H04L29/06 , H04L12/28
CPC分类号： H04L63/0227 , H04L63/102
摘要： An apparatus is provided that includes a processor configured to receive a captured traffic unit (CTU) intended for a network service, the CTU being one into which incoming traffic has been assembled based on a filter describing which incoming traffic to capture and how to assemble the respective incoming traffic into the CTU. The processor is also configured to determine whether to allow the CTU to pass to one or more applications configured to implement the respective network service based on a passlet including permissions to a particular user. The processor is further configured to instruct a firewall to allow the CTU to pass to the respective one or more applications or to reject the CTU based on the determination. In this regard, the processor is configured to perform the above functions under control of a security framework implemented in middleware between a user-level domain and a system-level domain.
摘要翻译：提供了一种装置，其包括被配置为接收用于网络服务的捕获的业务单元（CTU）的处理器，所述CTU是基于描述要捕获的进入流量以及如何组合相应的进入流量进入CTU。处理器还被配置为基于包括对特定用户的许可的密码来确定是否允许CTU传递到被配置为实现相应网络服务的一个或多个应用。处理器还被配置为指示防火墙允许CTU基于该确定传递到相应的一个或多个应用或拒绝CTU。在这方面，处理器被配置为在用户级域和系统级域之间的中间件实现的安全框架的控制下执行上述功能。

8. 发明专利

PL2326632T3 NOWY KOKRYSZTAŁ CHOLINY I EPALRESTATU 未知
公开(公告)号：PL2326632T3
公开(公告)日：2017-10-31
申请号：PL09812208
申请日：2009-09-03
申请人： BIONEVIA PHARMACEUTICALS INC
发明人： KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HOUSTON TRAVIS L
IPC分类号： C07D277/36 , A61K31/427 , A61P3/10 , A61P9/10 , A61P25/02 , A61P25/28 , C07D277/32

9. 发明专利

DK2326632T3 Nyt cholin-krystal af epalrestat 未知
公开(公告)号：DK2326632T3
公开(公告)日：2017-09-18
申请号：DK09812208
申请日：2009-09-03
申请人： BIONEVIA PHARMACEUTICALS INC
发明人： KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HOUSTON TRAVIS L
IPC分类号： C07D277/36 , A61K31/427 , A61P3/10 , A61P9/10 , A61P25/02 , A61P25/28 , C07D277/32

10. 发明专利

EA016904B1 НОВЫЙ ХОЛИНОВЫЙ СОКРИСТАЛЛ ЭПАЛРЕСТАТА 未知
公开(公告)号：EA016904B1
公开(公告)日：2012-08-30
申请号：EA201100245
申请日：2009-09-03
申请人： BIONEVIA PHARMACEUTICALS INC
发明人： KALOFONOS ISABEL , STAHLY G PATRICK , MARTIN-DOYLE WILLIAM , KALOFONOS DIMITRIS , STULTS JEFFREY S , HOUSTON TRAVIS L
IPC分类号： C07D277/36 , A61K31/19 , A61P3/10 , C07D277/32
摘要： Изобретениеотноситсяк областифармакологии, вчастностик новомухолиновомусокристаллуэпалрестата 5-[(1Z,2E)-2-метил-3-фенилпропенилиден]-4-оксо-2-тиоксо-3-тиазолидинуксуснойкислоты. Получаютновыйсокристаллхолинав соответствиис различнымивариантамиизобретения. Изобретениеотноситсятакжек фармацевтическимкомпозициям, содержащимновыйсокристаллхолина, исвязанос терапевтическимприменениемновогосокристаллахолинадлялеченияи/илипрофилактикиразличныхзаболеваний, включаялечениеи/илипрофилактикуосложненийдиабета, лечениеи/илипрофилактикугомоцистинурии, связаннойс уменьшениемуровнейгомоцистеинав сывороткекрови, ингибированиеальдозо-редуктазы, атакжесозданиекардиопротекторногоэффектау пациентовбездиабета.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式